Snehal S.  Patel net worth and biography

Snehal Patel Biography and Net Worth

Mr. Patel has over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry.  He has served as a consultant, manager, and advisor for R&D and manufacturing design, scale-up, and operations at multiple public and private biotech companies, working on clinical and pre-clinical assets in stem cell therapy, multiple sclerosis t-cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment.  Mr. Patel has also served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase, where he focused on healthcare and biotech financing and strategic transactions.  Prior to that, he worked in operations and business development at consulting firms and Bayer Corporation.  He received a BS in Chemical Engineering and an MS in Biochemical Engineering from the Massachusetts Institute of Technology, a Certificate in Project Management from the University of California at Berkeley, and an MBA from the University of Chicago.

What is Snehal S. Patel's net worth?

The estimated net worth of Snehal S. Patel is at least $70.47 million as of April 1st, 2024. Mr. Patel owns 5,350,777 shares of Greenwich LifeSciences stock worth more than $70,469,733 as of May 30th. This net worth evaluation does not reflect any other assets that Mr. Patel may own. Additionally, Mr. Patel receives an annual salary of $1,090,000.00 as CEO at Greenwich LifeSciences. Learn More about Snehal S. Patel's net worth.

How old is Snehal S. Patel?

Mr. Patel is currently 60 years old. There are 4 older executives and no younger executives at Greenwich LifeSciences. Learn More on Snehal S. Patel's age.

What is Snehal S. Patel's salary?

As the CEO of Greenwich LifeSciences, Inc., Mr. Patel earns $1,090,000.00 per year. Learn More on Snehal S. Patel's salary.

How do I contact Snehal S. Patel?

The corporate mailing address for Mr. Patel and other Greenwich LifeSciences executives is , , . Greenwich LifeSciences can also be reached via phone at 832-819-3232 and via email at [email protected]. Learn More on Snehal S. Patel's contact information.

Has Snehal S. Patel been buying or selling shares of Greenwich LifeSciences?

Within the last three months, Snehal S. Patel has bought $57,240.00 of Greenwich LifeSciences stock. Most recently, on Monday, April 1st, Snehal Patel bought 3,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $19.08 per share, with a total value of $57,240.00. Following the completion of the transaction, the chief executive officer now directly owns 5,350,777 shares of the company's stock, valued at $102,092,825.16. Learn More on Snehal S. Patel's trading history.

Who are Greenwich LifeSciences' active insiders?

Greenwich LifeSciences' insider roster includes Frank Daugherty (Insider), Kenneth Hallock (Director), David McWilliams (Director), Snehal Patel (CEO), and Jaye Thompson (VP). Learn More on Greenwich LifeSciences' active insiders.

Are insiders buying or selling shares of Greenwich LifeSciences?

During the last year, Greenwich LifeSciences insiders bought shares 19 times. They purchased a total of 52,150 shares worth more than $589,795.50. The most recent insider tranaction occured on April, 1st when CEO Snehal Patel bought 3,000 shares worth more than $57,240.00. Insiders at Greenwich LifeSciences own 52.9% of the company. Learn More about insider trades at Greenwich LifeSciences.

Information on this page was last updated on 4/1/2024.

Snehal S. Patel Insider Trading History at Greenwich LifeSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Buy3,000$19.08$57,240.005,350,777View SEC Filing Icon  
3/22/2024Buy2,500$19.98$49,950.005,347,777View SEC Filing Icon  
3/20/2024Buy1,500$17.68$26,520.005,345,277View SEC Filing Icon  
3/4/2024Buy4,100$13.03$53,423.005,340,277View SEC Filing Icon  
2/15/2024Buy12,700$11.07$140,589.005,325,377View SEC Filing Icon  
11/10/2023Buy5,000$10.17$50,850.005,312,677View SEC Filing Icon  
11/3/2023Buy3,500$9.11$31,885.005,307,677View SEC Filing Icon  
10/25/2023Buy2,500$7.91$19,775.005,301,677View SEC Filing Icon  
10/10/2023Buy1,000$9.07$9,070.005,299,177View SEC Filing Icon  
10/4/2023Buy2,000$8.63$17,260.005,298,177View SEC Filing Icon  
9/19/2023Buy4,000$8.95$35,800.005,296,177View SEC Filing Icon  
9/19/2023Buy4,000$8.95$35,800.005,296,177View SEC Filing Icon  
9/11/2023Buy1,000$9.48$9,480.005,292,177View SEC Filing Icon  
8/22/2023Buy1,000$9.97$9,970.005,291,177View SEC Filing Icon  
8/4/2023Buy2,000$10.55$21,100.005,290,177View SEC Filing Icon  
7/21/2023Buy1,000$9.20$9,200.005,288,177View SEC Filing Icon  
5/17/2023Buy1,000$11.69$11,690.005,287,177View SEC Filing Icon  
4/18/2023Buy2,000$11.12$22,240.005,279,177View SEC Filing Icon  
4/11/2023Buy5,000$12.42$62,100.005,271,177View SEC Filing Icon  
3/10/2023Buy1,000$12.12$12,120.002,737,486View SEC Filing Icon  
2/17/2023Buy600$16.53$9,918.002,736,486View SEC Filing Icon  
2/10/2023Buy1,000$18.68$18,680.002,735,886View SEC Filing Icon  
1/27/2023Buy2,000$19.35$38,700.002,734,886View SEC Filing Icon  
1/20/2023Buy1,500$17.37$26,055.002,732,886View SEC Filing Icon  
1/6/2023Buy1,500$15.18$22,770.002,731,386View SEC Filing Icon  
12/16/2022Buy1,000$13.01$13,010.002,725,886View SEC Filing Icon  
12/9/2022Buy2,000$13.11$26,220.002,724,886View SEC Filing Icon  
12/2/2022Buy1,000$13.84$13,840.002,722,886View SEC Filing Icon  
11/2/2022Buy2,000$8.79$17,580.002,721,886View SEC Filing Icon  
10/14/2022Buy3,000$9.75$29,250.002,719,886View SEC Filing Icon  
10/7/2022Buy2,000$9.72$19,440.002,716,886View SEC Filing Icon  
10/7/2022Buy2,000$9.72$19,440.002,716,886View SEC Filing Icon  
9/29/2022Buy1,000$9.23$9,230.002,713,886View SEC Filing Icon  
6/24/2022Buy22,535$9.13$205,744.552,706,421View SEC Filing Icon  
6/16/2022Buy8,000$7.13$57,040.002,683,886View SEC Filing Icon  
6/14/2022Buy12,000$7.91$94,920.002,675,886View SEC Filing Icon  
6/9/2022Buy4,500$10.90$49,050.001,243,453View SEC Filing Icon  
6/7/2022Buy6,000$8.55$51,300.001,238,953View SEC Filing Icon  
6/2/2022Buy6,774$7.38$49,992.121,223,703View SEC Filing Icon  
4/21/2022Buy6,000$16.09$96,540.001,216,929View SEC Filing Icon  
4/19/2022Buy6,000$16.74$100,440.001,210,929View SEC Filing Icon  
2/11/2022Buy5,500$19.80$108,900.00View SEC Filing Icon  
2/4/2022Buy5,000$19.59$97,950.00View SEC Filing Icon  
1/3/2022Buy2,050$23.82$48,831.00View SEC Filing Icon  
12/14/2021Buy1,840$27.17$49,992.80View SEC Filing Icon  
4/13/2021Buy2,700$36.98$99,846.001,189,539View SEC Filing Icon  
11/19/2020Buy2,000$5.40$10,800.001,186,839View SEC Filing Icon  
See Full Table

Snehal S. Patel Buying and Selling Activity at Greenwich LifeSciences

This chart shows Snehal Patel's buying and selling at Greenwich LifeSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Greenwich LifeSciences Company Overview

Greenwich LifeSciences logo
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More

Today's Range

Now: $13.17
Low: $12.57
High: $13.42

50 Day Range

MA: $15.03
Low: $12.07
High: $20.32

2 Week Range

Now: $13.17
Low: $7.58
High: $21.44


17,097 shs

Average Volume

41,355 shs

Market Capitalization

$169.63 million

P/E Ratio


Dividend Yield